Week 9: 3D bioprinting and biofabrication

What about this week on 3D bioprinting and biofabrication?

Nina Tandon (EpiBone), Bob Hendrikx

Biofabrication/h2>

Questions

From an ethical and moral standpoint, list pros and cons of working with hiPSCs as opposed to embryonic stem cells?

If we are to use organoid models as surrogates for in vivo tissues, what type of functional attributes would be critical to add/engineer into such organoid systems?

Can you think of any limitations in current organoid and or organ on a chip systems in recapitulating human biology?

If you were to theorize an experiment about improving current organoid models, which aspects of the microenvironment would you consider adding beyond chemical?

In the tissue engineering paradigm, what properties are important to provide from a scaffold and bioreactor?

Mycelium by Bob Hendrikx, Loop, TU Delft

Reference

    Requirement Background & Homework-Related Papers
  • Takahashi, K. and Yamanaka, S., 2016. A decade of transcription factor-mediated reprogramming to pluripotency. Nature reviews Molecular cell biology, 17(3), p.183.
  • Breckwoldt, K., Letuffe-Brenière, D., Mannhardt, I., Schulze, T., Ulmer, B., Werner, T., ... & Hansen, A. (2017). Differentiation of cardiomyocytes and generation of human engineered heart tissue. Nature protocols, 12(6), 1177.
  • Tandon, N., Cimetta, E., Bhumiratana, S., Godier-Furnemont, A., Maidhof, R., & Vunjak-Novakovic, G. (2013). Bioreactors for tissue engineering. In Biomaterials Science (pp. 1178-1194). Academic Press.
  • Bhumiratana, S., Bernhard, J. C., Alfi, D. M., Yeager, K., Eton, R. E., Bova, J., ... & Vunjak-Novakovic, G. (2016). Tissue-engineered autologous grafts for facial bone reconstruction. Science translational medicine, 8(343), 343ra83-343ra83.